Marshall Wace
HARP

Marshall Wace’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Marshall Wace’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,174
Closed -$137K – 3943
2022
Q2 		$137K Buy
+7,174
New +$186K ﹤0.01% 3235
2022
Q1 		– Sell
-23,550
Closed -$1.78M – 4250
2021
Q4 		$1.78M Buy
+23,550
New +$1.61M ﹤0.01% 2114
2020
Q4 		– Sell
-5,235
Closed -$889K – 2277
2020
Q3 		$889K Buy
+5,235
New +$755K 0.01% 1064
2019
Q4 		– Sell
-275
Closed -$38K – 2174
2019
Q3 		$38K Buy
+275
New +$38.7K ﹤0.01% 1529

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return

Marshall Wace's HARP Position: Q3 2022 in Review

Marshall Wace sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2022, closing a stake of 7,174 shares — an estimated $137K sold.

Marshall Wace first reported a position in HARP in Q3 2019 and held it in 4 quarters. The position peaked at $1.78M in Q4 2021. 52 funds tracked by Wall St. Rank hold HARP as of Q3 2022.

  • Marshall Wace reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Marshall Wace sold 7,174 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $137K.
  • Marshall Wace first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • Marshall Wace's Harpoon Therapeutics, Inc. Common Stock position peaked at $1.78M in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Marshall Wace's 13F filing for Q3 2022, filed 14 Nov 2022.